Riboflavin (Vitamin) : Physiology, Evidence, and Clinical Translation

Riboflavin: The Luminal Sentinel of Oxidative Metabolism, One-Carbon Homeostasis, and Epithelial Integrity

Riboflavin, vitamin B2, is a water-soluble micronutrient that serves as the obligate precursor for the flavin coenzymes, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). These coenzymes are not mere accessories; they are catalytic cornerstones of the electron transport chain, the tricarboxylic acid cycle, fatty acid oxidation, and the complex architecture of one-carbon metabolism. The isoalloxazine ring of the flavin coenzyme, with its capacity to undergo reversible single- and double-electron transfers, makes it a uniquely versatile redox center in a biological universe dominated by nicotinamides and hemes. Riboflavin is not synthesized by mammals. It is a dietary essential, and its absorption, cellular uptake, and conversion to active cofactors are tightly regulated processes that can be saturated or impaired, creating states of functional riboflavin deficiency that do not always register on standard plasma assays. This monograph is written for the clinician and scientist who seek to understand riboflavin not as a historical footnote in the story of vitamin discovery, but as a dynamic modulator of mitochondrial energetics, an epigenetic gatekeeper through its partnership with the methylenetetrahydrofolate reductase (MTHFR) enzyme, and a critical shield against the oxidative stress that underlies neurodegenerative disease and migraine pathogenesis. We dissect the transport systems that create tissue-specific riboflavin gradients, grade the clinical evidence for therapeutic riboflavin supplementation, and map the unresolved questions that define the frontier of flavin biology.

---

Part 1. The Structural and Chemical Identity of Riboflavin

Riboflavin is a tricyclic heterocycle derived from a 7,8-dimethyl-10-alkylisoalloxazine ring system. A ribityl side chain, a reduced form of ribose, is attached to the nitrogen at position 10. This ribityl chain is the molecular handle that is phosphorylated and adenylated to generate the active coenzymes. The isoalloxazine ring is planar and lipophilic, with the capacity to intercalate into proteins. The defining chemistry of riboflavin resides at the nitrogen atoms at positions 1 and 5 of the isoalloxazine ring, which can accept and donate single electrons, allowing flavins to stabilize semiquinone radical intermediates. This property makes FAD and FMN the only coenzymes in human biology capable of both one-electron and two-electron transfer reactions, a requirement for coupling the two-electron donors NADH and succinate to the single-electron carrier ubiquinone in Complex I and Complex II of the mitochondrial respiratory chain.

1A. The Biosynthetic Impossibility: Why Riboflavin Is Essential

Plants, fungi, and bacteria synthesize riboflavin from guanosine triphosphate (GTP) and ribulose-5-phosphate through a conserved pathway that involves the enzymes GTP cyclohydrolase II, pyrimidine deaminase, and lumazine synthase. This pathway is absent in humans. Riboflavin is a vitamin, derived exclusively from the diet. The recommended dietary allowance for adults is 1.3 milligrams per day for men and 1.1 milligrams per day for women, with increased requirements during pregnancy (1.4 milligrams) and lactation (1.6 milligrams). Rich dietary sources include dairy milk, eggs, lean meats, liver, almonds, and green vegetables. Milk is a particularly bioavailable source, with riboflavin bound to specific binding proteins that protect it from photodegradation. Cereal grains are poor sources unless fortified, and populations that rely heavily on unfortified grains and avoid dairy products are at risk for subclinical riboflavin deficiency.

1B. The Pathway to the Active Coenzyme: From Vitamin to Catalyst

Dietary riboflavin, mainly in the form of FAD and FMN bound to proteins, is liberated by gastric acidification and intestinal phosphatases. Free riboflavin is absorbed in the proximal small intestine via a saturable, carrier-mediated transport system, the riboflavin transporters RFVT1, RFVT2, and RFVT3. Once inside the enterocyte, riboflavin is converted to its active coenzyme forms through two sequential ATP-dependent enzymatic reactions. First, riboflavin kinase phosphorylates the ribityl side chain at the 5'-hydroxyl group to yield FMN. FMN can then be converted to FAD by FAD synthetase, which transfers an adenosyl monophosphate group from ATP to the phosphate of FMN. This conversion is not unidirectional; FAD can be hydrolyzed back to FMN by FAD pyrophosphatase, creating a controlled equilibrium between the two coenzyme pools.

The intracellular distribution of riboflavin, FMN, and FAD is governed by a partitioning system. Most FAD and FMN are covalently or tightly non-covalently bound to apoenzymes, forming flavoproteins. Free flavins constitute a minor fraction. The mitochondrial pool of FAD is critical; it is here that FAD-dependent dehydrogenases of the electron transport chain and fatty acid oxidation reside. The cytoplasmic pool of FMN and FAD supports a distinct set of enzymes, including the MTHFR and the NADPH oxidases.

---

Part 2. The Coenzyme Biology: A Redox Nexus

The functional biology of riboflavin is the biology of its flavoprotein progeny. The human proteome contains approximately 90 flavoprotein genes, and the flavin coenzyme is the catalytic center of a disparate array of reactions that converge on the transfer of electrons.

2A. Complex I and Complex II: The Mitochondrial Electron Entry Points

The mitochondrial electron transport chain depends on riboflavin at two critical entry points. Complex I, the NADH dehydrogenase, is an enormous multi-subunit enzyme that contains an FMN molecule and eight iron-sulfur clusters. The FMN accepts two electrons from NADH and passes them singly through the iron-sulfur chain to ubiquinone. This is the major source of proton motive force and ATP in aerobic metabolism. A functional riboflavin deficit manifests first in tissues with high Complex I activity, notably the brain, the retina, and the cardiac muscle.

Complex II, succinate dehydrogenase, is a direct participant in both the electron transport chain and the tricarboxylic acid cycle. It contains a covalently bound FAD molecule that oxidizes succinate to fumarate, passing the electrons to ubiquinone via iron-sulfur clusters. This is the only membrane-bound enzyme of the TCA cycle, and its FAD cofactor is irreplaceable.

2B. Fatty Acid Oxidation and the Acyl-CoA Dehydrogenases

The mitochondrial oxidation of fatty acids proceeds through a cycle of dehydrogenation, hydration, a second dehydrogenation, and thiolytic cleavage. The first step, the transfer of electrons from an acyl-CoA ester to the electron transfer flavoprotein (ETF), is catalyzed by acyl-CoA dehydrogenases. These are FAD-dependent enzymes. Very long-chain, medium-chain, and short-chain acyl-CoA dehydrogenases each use a tightly bound FAD to abstract a proton and a hydride from their substrates. The electrons are then passed from reduced ETF to ETF-ubiquinone oxidoreductase, another FAD-dependent enzyme, which delivers them to the ubiquinone pool. A riboflavin-deficient state impairs fatty acid oxidation, producing a lipid myopathy, non-ketotic hypoglycemia, and the accumulation of acylcarnitines, a metabolic signature that overlaps with the inborn errors of metabolism that affect these same enzymes.

2C. The MTHFR Link: Riboflavin as an Epigenetic Cofactor

The interface between riboflavin and one-carbon metabolism is mediated by the enzyme MTHFR, an FAD-dependent oxidoreductase that converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the primary circulating form of folate and the methyl donor for the remethylation of homocysteine to methionine. The MTHFR enzyme uses FAD to accept electrons from NADPH, maintaining its catalytic machinery in a reduced state. The FAD cofactor is not a stoichiometric reactant; it is a prosthetic group that is required for the structural integrity and redox tuning of the enzyme.

A common polymorphism in the MTHFR gene, the C677T variant, encodes a thermolabile enzyme with reduced activity and an increased tendency to lose its FAD cofactor. Individuals who are homozygous for the 677T allele (TT genotype) have an elevated plasma homocysteine concentration, particularly when riboflavin status is marginal. The binding of FAD to the MTHFR variant protein is less stable, and a higher intracellular FAD concentration is required to saturate the enzyme and maintain its activity. Riboflavin status, therefore, is a modifier of the MTHFR C677T phenotype. In riboflavin-replete individuals, the effect of the TT genotype on homocysteine is attenuated. In riboflavin-deficient individuals, the effect is unmasked. This gene-nutrient interaction is a model for understanding the role of riboflavin in complex disease risk.

---

Part 3. The Tissue-Specific Biology of Riboflavin

The distribution of riboflavin, the expression of its transporters, and the profile of its dependent enzymes create tissue-specific vulnerabilities to riboflavin insufficiency.

3A. The Nervous System: Myelin, Mitochondria, and Migraine

The central and peripheral nervous systems are critically dependent on mitochondrial ATP production and on the structural integrity of myelin. Riboflavin is required for the synthesis of the fatty acids that are incorporated into myelin, and the FAD-dependent dehydrogenases of the mitochondrial electron transport chain are the primary source of energy for neurons and glial cells. A riboflavin deficit in the nervous system produces a metabolic encephalopathy and a peripheral neuropathy that can be mistaken for other degenerative or nutritional disorders.

The role of riboflavin in migraine prophylaxis is a distinct clinical entity. The mitochondrial hypothesis of migraine proposes that an impairment of brain mitochondrial energy metabolism triggers the cortical spreading depression and trigeminovascular activation that underlie migraine attacks. Riboflavin, as the precursor of the Complex I and Complex II cofactors, is a rational intervention to improve the efficiency of mitochondrial oxidative phosphorylation in the brain. A randomized, placebo-controlled trial of high-dose riboflavin, 400 milligrams per day, demonstrated a significant reduction in migraine attack frequency compared to placebo, establishing riboflavin as a first-line prophylactic agent in migraine, particularly for patients who cannot tolerate or prefer to avoid standard pharmacotherapy.

3B. The Ocular Surface and the Cornea

The corneal epithelium is an avascular, transparent tissue that is exposed to ultraviolet radiation and oxygen, a combination that generates reactive oxygen species. The corneal epithelium is one of the most metabolically active tissues in the body, with a high density of mitochondria. Riboflavin is concentrated in the cornea, and its deficiency produces a characteristic superficial keratitis with vascularization of the cornea, a hallmark of classic ariboflavinosis. This reflects a failure of the FAD-dependent glutathione reductase to regenerate reduced glutathione, the major intracellular antioxidant, leading to oxidative damage to the corneal epithelium. Beyond deficiency, riboflavin is used therapeutically in ophthalmology as a photosensitizer for corneal collagen cross-linking, a procedure that stabilizes the corneal stroma in keratoconus. This application exploits the photochemical properties of riboflavin, not its vitamin function.

3C. The Skin, the Mucosal Epithelium, and the Wound

The clinical syndrome of riboflavin deficiency, ariboflavinosis, is characterized by a triad of lesions: angular stomatitis (fissuring and inflammation at the corners of the mouth), cheilosis (swelling, redness, and cracking of the lips), and a magenta glossitis (a sore, red, and atrophic tongue). These are tissues with a high rate of epithelial turnover, and their failure in riboflavin deficiency reflects the impairment of mitochondrial energy production required for cell proliferation and the failure of the FAD-dependent pyridoxine phosphate oxidase that converts dietary vitamin B6 to its active coenzyme form, pyridoxal 5'-phosphate. The skin, the oral mucosa, and the gastrointestinal epithelium are histological windows into cellular riboflavin status.

---

Part 4. The Clinical Taxonomy of Riboflavin Insufficiency

Overt ariboflavinosis with the classic dermatological and oral mucosal findings is rare in developed nations, but it remains a significant problem in regions where the diet is heavily dependent on polished rice. The more pervasive and clinically relevant entity is functional riboflavin insufficiency, a state in which plasma riboflavin levels are within the reference range, but intracellular flavin coenzyme pools are inadequate to saturate critical apoenzymes, particularly in tissues with high energy demands or in individuals with polymorphisms that reduce coenzyme binding affinity.

4A. Dietary Inadequacy, Lactose Intolerance, and the Elderly

The richest source of bioavailable riboflavin in the Western diet is dairy milk. Populations that avoid dairy due to lactose intolerance, cultural dietary patterns, or poverty are at increased risk for marginal riboflavin status. The elderly, who may have reduced caloric intake and a higher prevalence of lactose intolerance, are particularly susceptible. A non-specific presentation of weakness, anemia, and angular stomatitis in an elderly patient should include riboflavin deficiency in the differential diagnosis, as it is readily treatable.

4B. Endocrine Disorders, Thyroid Hormone, and Antipsychotics

The conversion of riboflavin to FMN and FAD is under endocrine control. Thyroid hormones, triiodothyronine and thyroxine, stimulate riboflavin kinase activity. In hypothyroidism, the synthesis of flavin coenzymes is impaired, and signs of riboflavin deficiency can appear even with adequate dietary intake. Conversely, the administration of chlorpromazine and other tricyclic antipsychotics can inhibit the conversion of riboflavin to FMN, and tricyclic antidepressants can increase the urinary excretion of riboflavin. The clinical significance of these drug-nutrient interactions is not fully defined, but they contribute to the heterogeneity of riboflavin status in psychiatric populations.

4C. The MTHFR C677T Polymorphism as a Riboflavin-Responsive State

Approximately 10 to 15 percent of populations of European and Hispanic ancestry are homozygous for the MTHFR C677T (TT) genotype. These individuals have a flavoprotein that is more dependent on adequate intracellular FAD concentrations for its catalytic function and structural stability. In a state of marginal riboflavin intake, the TT genotype is associated with hyperhomocysteinemia, an independent risk factor for cardiovascular disease and stroke. Riboflavin supplementation in these individuals, at doses of 1.6 to 10 milligrams per day, significantly and specifically lowers plasma homocysteine, an effect that is not seen in individuals with the CC genotype. This is a classic example of a nutrigenetic intervention: a targeted nutrient therapy for a genetically defined subgroup.

---

Part 5. The Evidence Mapped by Quality and Clinical Application

The clinical evidence for riboflavin is stratified, with a strong evidence base for migraine prophylaxis and for the nutrigenetic management of the MTHFR polymorphism, and a supportive but less mature evidence base for other applications.

5.1. Riboflavin as Standard Therapy in Migraine Prophylaxis

The evidence for riboflavin in migraine prophylaxis is derived from randomized controlled trials. A high-dose regimen of 400 milligrams of riboflavin per day reduced monthly migraine attack frequency by approximately 50 percent compared to a 15 percent reduction with placebo, with a number needed to treat comparable to that of established prophylactic agents like beta-blockers and topiramate. The safety profile is superior: riboflavin is not associated with the cognitive side effects of topiramate or the fatigue and bradycardia of beta-blockers. The mechanism is a stabilization of mitochondrial energy metabolism in the brain, reducing the threshold for cortical spreading depression. The clinical use of riboflavin at this dose is a cornerstone of evidence-based nutraceutical neurology.

5.2. MTHFR C677T, Homocysteine, and Blood Pressure

The riboflavin-MTHFR interaction has been studied most intensively in the context of cardiovascular disease risk. In patients who are homozygous for the MTHFR 677T allele, riboflavin supplementation at a low dose of 1.6 milligrams per day for 12 weeks reduced plasma homocysteine by up to 40 percent. A post hoc analysis of a cardiovascular prevention trial found that riboflavin supplementation, in conjunction with folate, significantly reduced systolic blood pressure specifically in the TT genotype subgroup, an effect that was not attributable to homocysteine lowering alone and may involve a direct effect of FAD on vascular nitric oxide biology. This positions riboflavin as a targeted agent for the management of hypertension in a genetically defined population, a personalized nutrition strategy that awaits validation in a prospective, genotype-stratified randomized trial with incident cardiovascular events as the endpoint.

5.3. Riboflavin in Anemia and Iron Absorption

Riboflavin is a cofactor for the enzyme pyridoxine phosphate oxidase, which converts vitamin B6 to its active form, pyridoxal 5'-phosphate, required for heme synthesis. Riboflavin deficiency impairs the mobilization of iron from ferritin and its incorporation into hemoglobin. In populations with a high prevalence of both riboflavin deficiency and iron deficiency anemia, riboflavin supplementation improves the hematological response to iron therapy. This is a synergistic nutrient interaction, not a direct effect of riboflavin on erythropoiesis, and it underscores the principle that a single micronutrient deficiency is rarely isolated in clinical practice.

5.4. The Frontier of Neurodegeneration: Parkinson's Disease and Multiple Sclerosis

The role of mitochondrial Complex I dysfunction in the pathogenesis of Parkinson's disease is established. Riboflavin, as the precursor of the FMN cofactor of Complex I, is a rational candidate for neuroprotection. Small pilot studies have explored high-dose riboflavin in Parkinson's disease, with some evidence for an improvement in motor function, particularly when combined with a dietary strategy to reduce coenzyme Q10 oxidation and iron accumulation. The evidence is preliminary and insufficient for a clinical recommendation.

In multiple sclerosis, axonal degeneration is driven by mitochondrial failure and oxidative stress. Riboflavin, by supporting mitochondrial energy metabolism and glutathione regeneration via FAD-dependent glutathione reductase, is a candidate for a neuroprotective adjunct to immunomodulatory therapy. Clinical trials are lacking, but the mechanistic rationale is sound.

---

Part 6. A Clinical Dosing Compendium

The dosing of riboflavin is regimen-specific, defined by the clinical objective and the pharmacological properties of riboflavin absorption and saturation.

6.1. Evidence-Based and Guideline-Supported Protocols

Migraine Prophylaxis. The established dose is 400 milligrams of riboflavin per day, taken orally. This dose is typically administered as a single 400-milligram capsule, as absorption is saturable, and divided dosing does not significantly increase bioavailability. The clinical effect is not immediate; a trial of at least 3 months is recommended before assessing efficacy. The adverse effect profile is benign, with a notable but harmless yellow-orange discoloration of the urine, which is a direct manifestation of renal riboflavin excretion and confirms compliance.

MTHFR C677T-Associated Hyperhomocysteinemia. A dose of 1.6 milligrams per day, a near-physiological dose achievable through fortified foods or a dedicated supplement, is sufficient to lower homocysteine specifically in individuals with the TT genotype. Higher doses are not required for this effect, as the aim is to saturate the MTHFR apoenzyme, a target that is achieved at low intracellular FAD concentrations. The role of riboflavin in this context is as a targeted cofactor therapy, not a pharmacological intervention.

Overt Riboflavin Deficiency (Ariboflavinosis). The treatment dose is 5 to 30 milligrams per day, administered orally in divided doses, usually for a period of weeks until the clinical lesions of the skin and mucosa have resolved, followed by a maintenance dose consistent with the recommended dietary allowance.

6.2. Theoretical and Postulated Dosing Frameworks

Neuroprotection in Parkinson's Disease. Rationale: to bypass potential defects in riboflavin transport or kinase activity in the brain and to saturate the FMN-binding site of mitochondrial Complex I. Postulate: an oral dose of 30 to 60 milligrams of riboflavin, three times daily, for a total daily dose of 90 to 180 milligrams, in combination with a reduced iron diet and Coenzyme Q10, for patients with early-stage Parkinson's disease. The primary endpoint would be the change in the motor subscale of the Unified Parkinson's Disease Rating Scale (UPDRS) over 12 months. The safety of chronic high-dose riboflavin at this level, while not fully characterized, is supported by its low toxicity profile.

Adjunctive Therapy in Multiple Sclerosis. Rationale: to support axonal mitochondrial metabolism and to enhance the reduction of oxidized glutathione, mitigating oxidative damage to oligodendrocytes and axons. Postulate: a dose of 100 milligrams of riboflavin, twice daily, as an adjunct to standard disease-modifying therapy in patients with relapsing-remitting multiple sclerosis. The primary endpoint would be a reduction in the rate of brain volume loss on serial MRI, a biomarker of neuroaxonal degeneration.

Riboflavin for Corneal Cross-Linking (Ophthalmology). This is a procedural, not an oral, use. Riboflavin 0.1 percent solution, combined with dextran, is applied to the deepithelialized cornea and activated by ultraviolet A light. The riboflavin acts as a photosensitizer, generating reactive oxygen species that form covalent cross-links between collagen fibrils in the corneal stroma, stiffening the cornea and halting the progression of keratoconus. This is a highly specialized, hospital-based procedure and is distinct from nutritional supplementation.

6.3. Universal Principles Governing Riboflavin Supplementation

Absorption Is Saturable. The active transport of riboflavin in the small intestine is a capacity-limited system. Single oral doses above approximately 30 milligrams are absorbed less efficiently than lower doses. For high-dose therapy, such as in migraine prophylaxis, the proportion of the dose absorbed is small, but the absolute amount absorbed is sufficient to achieve therapeutic effect. The co-administration of riboflavin with food enhances its absorption by slowing gastrointestinal transit and increasing the exposure of the transporter to the substrate.

The Therapeutic Window Is Wide. Riboflavin has no defined tolerable upper intake level. The toxicity is negligible because of the saturable absorption and a rapid renal clearance of the vitamin. The only consistent consequence of high-dose riboflavin is a bright yellow urine, which is harmless. This does not mean that supratherapeutic doses are without any theoretical risk; riboflavin is a photosensitizer, and a theoretical, unproven risk of lenticular or retinal photodamage with prolonged, extreme high-dose supplementation in the context of intense light exposure exists in the literature, but it has never been documented in humans.

Tissue Status Is Not Accurately Reflected by Plasma Riboflavin. Plasma riboflavin concentration is a poor functional marker. The erythrocyte glutathione reductase activation coefficient (EGRAC) is a functional assay that measures the activity of glutathione reductase in red blood cells before and after the addition of exogenous FAD. An elevated EGRAC indicates a functional deficiency of FAD, even when plasma riboflavin is normal. This assay is a more meaningful biomarker for clinical and research purposes than a simple plasma level, but it is not widely available in clinical laboratories.

---

Part 7. The Unresolved Frontier

Three specific questions define the current limit of riboflavin science.

Does High-Dose Riboflavin Alter the Course of Complex I-Dependent Neurodegeneration? Parkinson's disease is characterized by a failure of Complex I. Riboflavin is the only known substrate that can drive an increase in the mitochondrial FMN pool. The question is whether long-term, high-dose riboflavin can rescue the Complex I defect in vivo in the human substantia nigra, and whether this translates to a clinically meaningful slowing of disease progression. A randomized, double-blind, placebo-controlled trial with a robust neuroimaging biomarker and long-term clinical follow-up is required.

What Is the Mechanism of the Riboflavin-MTHFR Genotype Effect on Blood Pressure? The observation that riboflavin lowers blood pressure specifically in the MTHFR TT genotype, independent of homocysteine lowering, points to a flavin-dependent mechanism in vascular biology. This could involve the nitric oxide synthase enzymes, the NADPH oxidases that generate superoxide, or the cytochrome P450 enzymes that generate vasoactive eicosanoids. The identification of this mechanism would define a new dimension of flavin biology in vascular function and could lead to genotype-based dietary guidelines for the prevention of hypertension.

Can Riboflavin Serve as a "Master Cofactor" for Multienzyme Complexes in the Brain? The brain contains a distinct mitochondrial riboflavin kinase and FAD synthetase that are regulated by different signals than their peripheral counterparts. The functional organization of flavin cofactor delivery to specific mitochondrial enzyme complexes is a biological black box. It is not known whether flavin coenzymes are directly channeled from the kinase and synthetase to Complex I, or whether they equilibrate with a free pool. Understanding this biology could lead to new strategies for targeting flavin cofactor delivery to specific enzymes in the brain, a form of subcellular precision nutrition.

---

Part 8. Synthesis for an Evidence-Based Approach

Riboflavin is a vitamin that functions as a cofactor precursor, and its clinical significance is determined by the biology of the flavoproteins. It is essential for mitochondrial ATP production, for the beta-oxidation of fatty acids, and for the regulation of the one-carbon cycle through its partnership with MTHFR. The clinical use of riboflavin is anchored by a high-quality evidence base for migraine prophylaxis at a pharmacological dose of 400 milligrams per day and for the nutrigenetic management of MTHFR C677T-associated hyperhomocysteinemia at a physiological dose of 1.6 milligrams per day.

The spectrum of riboflavin-responsive disease is expanding, driven by the recognition that functional flavin insufficiency can occur in the absence of the classic deficiency syndrome. The interaction between riboflavin status and the MTHFR polymorphism is a model for how a micronutrient can modify the penetrance of a genetic variant. The role of riboflavin in neurodegenerative disease is a frontier that is built on the role of Complex I in mitochondrial pathology, but it lacks the clinical trial evidence that would translate the mechanistic rationale into a standard of care.

The safety and low cost of riboflavin make it an unusually practical intervention. The saturable absorption and the renal clearance of excess vitamin provide a natural ceiling on systemic exposure and toxicity. The clinician who considers riboflavin for a patient with migraine, for a hypertensive patient with the MTHFR TT genotype, or for a patient with an unexplained peripheral neuropathy or corneal surface disease, is standing on firm mechanistic ground. The recognition that riboflavin is not merely a vitamin but a regulator of the redox and epigenetic landscape of the cell, is the conceptual frame that transforms riboflavin from a nutritional footnote into a clinically significant nutraceutical.